James Neville Fairbairn - Net Worth and Insider Trading

James Neville Fairbairn Net Worth

The estimated net worth of James Neville Fairbairn is at least $4,424 dollars as of 2024-11-13. James Neville Fairbairn is the Senior Officer of XORTX Therapeutics Inc and owns about 2,366 shares of XORTX Therapeutics Inc (TSXV:XRTX) stock worth over $4,424. Details can be seen in James Neville Fairbairn's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that James Neville Fairbairn has not made any transactions after 2020-10-13 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of James Neville Fairbairn

James Neville Fairbairn Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, James Neville Fairbairn owns 1 companies in total, including XORTX Therapeutics Inc (TSXV:XRTX) .

Click here to see the complete history of James Neville Fairbairn’s form 4 insider trades.

Insider Ownership Summary of James Neville Fairbairn

Ticker	Comapny	Transaction Date	Type of Owner
TSXV:XRTX	XORTX Therapeutics Inc	2020-10-13	Senior Officer

James Neville Fairbairn Latest Holdings Summary

James Neville Fairbairn currently owns a total of 1 stock. James Neville Fairbairn owns 2,366 shares of XORTX Therapeutics Inc (TSXV:XRTX) as of October 13, 2020, with a value of $4,424.

Latest Holdings of James Neville Fairbairn

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
TSXV:XRTX	XORTX Therapeutics Inc	2020-10-13	2,366	1.87	4,424

Holding Weightings of James Neville Fairbairn

James Neville Fairbairn Form 4 Trading Tracker

According to the SEC Form 4 filings, James Neville Fairbairn has made a total of 3 transactions in XORTX Therapeutics Inc (TSXV:XRTX) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in XORTX Therapeutics Inc is the acquisition of 473 shares on October 13, 2020, which cost James Neville Fairbairn around $792,449.

Insider Trading History of James Neville Fairbairn

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

James Neville Fairbairn Trading Performance

GuruFocus tracks the stock performance after each of James Neville Fairbairn's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by James Neville Fairbairn is 9.95%. GuruFocus also compares James Neville Fairbairn's trading performance to market benchmark return within the same time period. The performance of stocks bought by James Neville Fairbairn within 3 months outperforms 2 times out of 5 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how James Neville Fairbairn's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of James Neville Fairbairn

Average Return

Average return per transaction

Outperforming Transactions

3 out of 5 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-3.85
Relative Return to S&P 500(%)	-7.2

James Neville Fairbairn Ownership Network

Ownership Network List of James Neville Fairbairn

No Data

Ownership Network Relation of James Neville Fairbairn

James Neville Fairbairn Owned Company Details

What does XORTX Therapeutics Inc do?

Who are the key executives at XORTX Therapeutics Inc?

James Neville Fairbairn is the Senior Officer of XORTX Therapeutics Inc. Other key executives at XORTX Therapeutics Inc include Director & Senior Officer Allen Warren Davidoff , and Senior Officer Amar Deep Keshri .

XORTX Therapeutics Inc (TSXV:XRTX) Insider Trades Summary

Over the past 18 months, James Neville Fairbairn made no insider transaction in XORTX Therapeutics Inc (TSXV:XRTX). Other recent insider transactions involving XORTX Therapeutics Inc (TSXV:XRTX) include a net purchase of 10,300 shares made by Allen Warren Davidoff ,

In summary, during the past 3 months, insiders sold 0 shares of XORTX Therapeutics Inc (TSXV:XRTX) in total and bought 5,300 shares, with a net purchase of 5,300 shares. During the past 18 months, 0 shares of XORTX Therapeutics Inc (TSXV:XRTX) were sold and 10,300 shares were bought by its insiders, resulting in a net purchase of 10,300 shares.

XORTX Therapeutics Inc (TSXV:XRTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

XORTX Therapeutics Inc Insider Transactions

No Available Data

James Neville Fairbairn Mailing Address

Above is the net worth, insider trading, and ownership report for James Neville Fairbairn. Currently GuruFocus does not have mailing address information for James Neville Fairbairn.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.